Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT

Bone Marrow Transplantation

Volumn 48, Issue 1, 2013, Pages 46-49

  Hudspeth, M P ^a   Heath, T S ^b   Chiuzan, C ^c   Garrett Mayer, E ^c   Nista, E ^a   Burton, L ^a   Ragucci, D ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Folinic acid; GVHD; MTX

Indexed keywords

CYCLOSPORIN; FOLINIC ACID; METHOTREXATE;

ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG FATALITY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPROPHYLAXIS; INFANT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RELAPSE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCHOOL CHILD; VEIN OCCLUSION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG MONITORING; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; FEMALE; FOLIC ACID ANTAGONISTS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUCOVORIN; MALE; METHOTREXATE; MUCOSITIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; VITAMIN B COMPLEX;

EID: 84872158119     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.82     Document Type: Article

References (32)

1. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides 2010; Available at: http://www.cibmtr. org.
2. Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325-1334. (Pubitemid 15057938)
3. Storb R, Deeg HJ, Thomas ED, Appelbaum FR, Buckner CD, Cheever MA et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985; 66: 698-702. (Pubitemid 15230779)
4. Irle C, Deeg HJ, Buckner CD, Kennedy M, Clift R, Storb R et al. Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. Leuk Res 1985; 9: 1255-1261. (Pubitemid 16228108)
5. Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K et al. Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of intolerance. Transplantation 1982; 34: 30-35. (Pubitemid 12099644)
6. Deeg HJ, Storb R, Appelbaum FR, Kennedy MS, Graham TC, Thomas ED. Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. Transplantation 1984; 37: 62-65. (Pubitemid 14178799)
7. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729-735. (Pubitemid 16124386)
8. Gratwohl AA, Bull MI, Graw Jr RG, Norton L, Knutsen T. Methotrexate and citrovorum factor after histoincompatible allogeneic bone marrow transplants in dogs. Acta Haematol 1978; 60: 233-242. (Pubitemid 8407019)
9. Torres A, Martinez F, Gomez P, Herrera C, Rojas R, Gomez-Villagran JL et al. Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation. Blut 1989; 58: 63-68. (Pubitemid 19061008)
10. Nevill TJ, Tirgan MH, Deeg HJ, Klingemann HG, Reece DE, Shepherd JD et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 9: 349-354.
11. Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1994; 14: 397-401. (Pubitemid 24295232)
12. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759-764. (Pubitemid 27207889)
13. Bhurani D, Schifter M, Kerridge I. Folinic acid administrations following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand. Bone Marrow Transplant 2008; 42: 547-550.
14. Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F et al. European Group for Blood and Marrow Transplantation (EBMT) Working Party Paediatric Diseases; International BFM Study Group-Subcommittee Bone Marrow Transplantation (IBFM-SG). Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405-411.
15. Storb R, Antin JH, Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant 2010; 16: S18-S27.
16. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314. (Pubitemid 28452971)
17. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
18. Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al. Acute graftversus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-1845.
19. Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ et al. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant 2002; 31: 73-75.
20. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-828.
21. Atkinson K, Downs K. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe graft versus host disease, relapse rate, or survival after HLA-identical sibling bone marrow transplantation. Bone Marrow Transplant 1995; 16: 755-758. (Pubitemid 26008432)
22. Yanik G, Levine JE, Ratanatharathorn V, Dunn R, Ferrara J, Hutchinson RJ. Tacrolimus and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26: 161-167. (Pubitemid 30496962)
23. Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K et al. Efficacy of folinic acid on preventing oral mucositis in allogeneic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant 2012; 47: 258-264.
24. Robien K, Schubert MM, Yasui Y, Martin P, Storb R, Potter JD et al. Folic acid supplementation during methotrexate immunosuppression is not assoiciated with early toxicity, risk of acute graft-versus-host-disease or relapse following hematopoietic transplantation. Bone Marrow Transplant 2006; 37: 687-692.
25. Ulrich C, Yasui Y, Storb R, Schubert M, Wagner JL, Bigler J. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 231-234.
26. Robien K, Schubert MM, Chay T, Bigler J, Storb R, Yasui Y et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 799-800.
27. Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R et al. Donor methylenetetrahydrofolate reducatse genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 2006; 37: 773-779.
28. Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R et al. The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexatetreated allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant 2012; 18: 722-730.
29. Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621-625. (Pubitemid 39341543)
30. Perkins J, Field T, Kim J, Kharfan-Dabaja M, Fernandez H, Ayala E et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010; 16: 937-947.
31. Ohata K, Espinoza JL, Lu X, Kondo Y, Nakao S. Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant 2011; 17: 205-213.
32. Leung W. Use of NK cell activity in cure of transplant. Br J Haematol 2011; 155: 14-29.